US Stock MarketDetailed Quotes
COEP Coeptis Therapeutics
- 0.200
- -0.039-16.25%
Close Dec 4 16:00 ET
- 0.194
- -0.005-2.71%
Post 19:26 ET
8.21MMarket Cap-712P/E (TTM)
0.230High0.193Low1.70MVolume0.227Open0.238Pre Close357.11KTurnover5.15%Turnover RatioLossP/E (Static)41.12MShares1.14052wk High1.71P/B6.60MFloat Cap0.15152wk Low--Dividend TTM33.04MShs Float21.420Historical High--Div YieldTTM15.65%Amplitude0.151Historical Low0.209Avg Price1Lot Size
About Coeptis Therapeutics Company
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
Company Profile
SymbolCOEP
Company NameCoeptis Therapeutics
Listing DateDec 17, 2020
Founded2017
CEOMr. David Mehalick
MarketNASDAQ
Employees7
Fiscal Year Ends12-31
Address105 Bradford Road,Suite 420
CityWexford
ProvincePennsylvania
CountryUnited States of America
Zip Code15090
Phone1-724-934-6467
Websitehttp://www.coeptistx.com
Company Executives
- Name
- Position
- Salary
- David Mehalick
- Chairman of the Board, President and Chief Executive Officer
- 18.33K
- Brian Cogley
- Chief Financial Officer
- 208.00K
- Dr. Colleen Delaney, M.D.
- Chief Scientific and Medical Officer
- 360.00K
- Christine Sheehy
- Vice President, Compliance and Corporate Secretary
- 151.00K
- Daniel Yerace
- Director and Vice President, Operations
- 18.33K
- Christopher Calise
- Director
- 18.33K
- Philippe Deschamps
- Independent Director
- 18.33K
- Dr. Tara Maria DeSilva
- Independent Director
- 18.33K
- Dr. Gene Salkind, M.D.
- Independent Director
- 18.33K
- Christopher Cochran
- Independent Director
- 18.33K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
